These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29796823)

  • 21. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S; Fleming DH; Mathew BS; Varughese S; Jeyaseelan V; Tamilarasi V; Jacob CK; John GT
    Ther Drug Monit; 2014 Aug; 36(4):423-32. PubMed ID: 25014074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study.
    Abe Y; Tada K; Yamaji K; Tamura N
    Biomed Res Int; 2021; 2021():8630596. PubMed ID: 33564682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis.
    Moore RA; Derry S
    Arthritis Res Ther; 2006; 8(6):R182. PubMed ID: 17163990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
    J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. To TDM or not to TDM in lupus nephritis patients treated with MMF?
    van Gelder T; Berden JH; Berger SP
    Nephrol Dial Transplant; 2015 Apr; 30(4):560-4. PubMed ID: 24811231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study.
    Goswami RP; Sircar G; Sit H; Ghosh A; Ghosh P
    J Clin Rheumatol; 2019 Jan; 25(1):28-35. PubMed ID: 29561474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
    Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
    Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report.
    Habuka M; Wada Y; Kurosawa Y; Yamamoto S; Tani Y; Ohashi R; Ajioka Y; Nakano M; Narita I
    BMC Res Notes; 2018 Mar; 11(1):165. PubMed ID: 29506558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
    Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
    Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
    Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.
    Cortés-Hernández J; Torres-Salido MT; Medrano AS; Tarrés MV; Ordi-Ros J
    Nephrol Dial Transplant; 2010 Dec; 25(12):3939-48. PubMed ID: 20538787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.
    Kasitanon N; Boripatkosol P; Louthrenoo W
    Int J Rheum Dis; 2018 Jan; 21(1):200-207. PubMed ID: 28901731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
    Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
    Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of trough mycophenolic acid levels for the management of lupus nephritis.
    Pourafshar N; Karimi A; Wen X; Sobel E; Pourafshar S; Agrawal N; Segal E; Mohandas R; Segal MS
    Nephrol Dial Transplant; 2019 Jan; 34(1):83-89. PubMed ID: 29548021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.